Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
LLY Price Action
Last 7 days
-6.3%
Last 30 days
11.4%
Last 90 days
-0.4%
Trailing 12 Months
11.9%
LLY Stock Price
LLY RSI Chart
LLY Valuation
LLY Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
LLY Fundamentals
LLY Revenue
LLY Earnings
LLY Profitability
LLY Investor Care
LLY Alerts
The Good News
Eli Lilly's stock surged over 14% after announcing positive trial results for orforglipron, a promising oral weight-loss drug, which may capture significant market share in obesity treatments (Sources: Markets Insider). Analysts are bullish on LLY, with a consensus Strong Buy rating and an average price target indicating substantial upside (Sources: Markets Insider).
The Bad News
Despite positive developments, Eli Lilly faces challenges, including a notable number of insider sales, indicating potential negative sentiment (Sources: Markets Insider). Additionally, the pharmaceutical industry is under pressure from upcoming tariffs and regulatory hurdles in Australia, which may impact future investments (Sources: Australian Financial Review).
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Product
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 49.0B | 0 | 0 | 0 |
| 2024 | 35.9B | 38.9B | 40.9B | 45.0B |
| 2023 | 27.7B | 29.5B | 32.1B | 34.1B |
| 2022 | 29.3B | 29.1B | 29.2B | 28.5B |
| 2021 | 25.5B | 26.7B | 27.8B | 28.3B |
| 2020 | 23.1B | 22.9B | 23.2B | 24.5B |
| 2019 | 21.6B | 21.7B | 21.8B | 22.3B |
| 2018 | 20.4B | 20.9B | 21.3B | 21.5B |
| 2017 | 20.9B | 20.6B | 20.3B | 20.0B |
| 2016 | 20.2B | 20.6B | 20.8B | 21.2B |
| 2015 | 19.6B | 19.6B | 19.7B | 20.0B |
| 2014 | 22.2B | 21.2B | 20.3B | 19.6B |
| 2013 | 22.6B | 22.9B | 23.3B | 23.1B |
| 2012 | 24.0B | 23.4B | 22.7B | 22.6B |
| 2011 | 23.4B | 23.9B | 24.4B | 24.3B |
| 2010 | 22.3B | 22.7B | 22.8B | 23.1B |
| 2009 | 20.6B | 20.8B | 21.1B | 21.8B |
| 2008 | 0 | 19.2B | 19.8B | 20.4B |
| 2007 | 0 | 0 | 0 | 18.6B |
Get all data in R, Python etc through our Historical Stock Data APIs
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
| CEO | Mr. David A. Ricks |
|---|---|
| WEBSITE | lilly.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 39000 |
